RxDoctor Payments Data

Diana Silva Cantillo, MD

Internal Medicine · Tucson, AZNPI 1003223686

Payments from drug & device makers

$1,138in general payments, 2019–2025

Across 20 payments — averaging $56.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$398
  • Viiv Healthcare Company$318
  • Janssen Scientific Affairs, LLC$167
  • Gilead$109
  • Merck$68
  • Johnson & Johnson$50
  • plus $28 from 1 others

What the payments were for

  • Food & beverage$74065%
  • Education$39835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,138 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$15,120
Medicare patients
68
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala261$1,048,705
DovatoDolutegravir Sodium/Lamivudine104$311,199
TriumeqAbacavir/Dolutegravir/Lamivudi62$238,424
DescovyEmtricitabine/Tenofov Alafenam93$203,139
TivicayDolutegravir Sodium63$164,150
JulucaDolutegravir/Rilpivirine39$137,879
GenvoyaElviteg/Cob/Emtri/Tenof Alafen32$128,601
IsentressRaltegravir Potassium47$123,957
PrezcobixDarunavir/Cobicistat49$109,200
PifeltroDoravirine35$66,239
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$45,867
EliquisApixaban22$32,847
PrezistaDarunavir15$29,225
OzempicSemaglutide18$27,566
Darunavir15$20,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$109$1,380,445386 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Juluca$318$851,652268 claims
MerckIsentress, Pifeltro$68$190,19682 claims
Johnson & JohnsonPrezcobix$50$109,20049 claims
Janssen Scientific Affairs, LLCPrezista$167$29,22515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →